[to top of second column]
"The implication would be that they might benefit from treatment," but that wasn't tested in the Texas study, said Brown, who has no ties to Genentech.
"We have struggled with what to do in women with very small tumors ... do they really need the nine yards?" said Dr. Claudine Isaacs, a breast specialist at Georgetown University's Lombardi Comprehensive Cancer Center who has been a paid speaker for Genentech.
Few women with small tumors were included in past studies of Herceptin and guidelines don't currently call for using the drug this way, she said.
On the Net:
Cancer conference: http://www.sabcs.org/
Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
< Recent articles
Back to top
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Law & Courts |
Spiritual Life |
Health & Fitness |
Calendar | Letters to the Editor